Call a Janssen CarePath Care Coordinator at 844-777-2828 Monday - Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support available.
to help navigate payer processes
Janssen CarePath helps verify insurance coverage for your patients prescribed SPRAVATO® and provides reimbursement information.
to help your patients start and stay on the treatment you prescribe
Janssen CarePath can help you find out what affordability assistance may be available for your patients taking SPRAVATO®.
to help your patients get informed and stay on SPRAVATO®
Janssen CarePath provides additional support to your patients, including patient education, web-based resources, and assistance finding a location that offers SPRAVATO® treatment.
Janssen CarePath Savings Program
Eligible commercially insured patients pay $10 per treatment for SPRAVATO® medication costs with a $7,150 maximum program benefit per calendar year
Treatment may include up to three devices administered on the same day. Program limits apply. Depending on how their insurance covers SPRAVATO®, there is a program benefit limit of list price of the medication and a quantity limit of three devices per day or up to 24 devices in the first 24-day period, and three devices per day or up to 23 devices in a 24-day period after the first 24-day period. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. Program does not cover the cost to give patients their treatment. See full eligibility requirements at Spravato.JanssenCarePathSavings.com.
Access & Reimbursement Guide
Information about coverage, coding, and the overall reimbursement process for SPRAVATO®.
Exceptions & Appeals Guide
Information for your certified SPRAVATO® treatment center, to help understand patients’ individual reimbursement scenarios.
SPRAVATO® (esketamine) CIII nasal spray is the S-enantiomer of racemic ketamine. SPRAVATO® is an FDA-approved nasal spray for TRD and MDSI. Ketamine infusion has not been approved by the FDA to treat depression. There are no head-to-head studies comparing esketamine and ketamine infusion. Both SPRAVATO® and ketamine are Schedule III controlled substances under the U.S. Controlled Substances Act.
There are no samples of SPRAVATO® available—in accordance with federal guidelines, which prohibit the distribution of samples of class III medications.
SPRAVATO® has a controlled distribution network that ensures SPRAVATO® is distributed only to certified healthcare settings and certified pharmacies. SPRAVATO® is not to be delivered directly to patients.
REMS-certified pharmacies follow standard acquisition protocols via full-line wholesalers and dispense SPRAVATO® to REMS-certified treatment centers.
REMS-certified healthcare centers can purchase SPRAVATO® directly from specialty distributors.
For a list of full-line wholesalers or specialty distributors and other downloadable resources, visit www.spravatotreatmentcenter.com/education.
SPRAVATO® should be administered in conjunction with an oral antidepressant (AD).
In TRD, the new open-label oral AD initiated during Study 1 (short-term) was an SSRI in 32% of patients and an SNRI in 68% of patients.
In MDSI trials for adults with MDSI, all patients received comprehensive standard-of-care treatment, including an initial inpatient hospitalization and a newly initiated or optimized oral AD therapy as determined by the investigator.
The cost of SPRAVATO® to your patients is dependent on their insurance plan. Janssen CarePath offers information on access and affordability resources for your patients, depending on their plan.
SPRAVATO® is only administered in a medically supervised healthcare setting that is certified under the SPRAVATO® REMS. SPRAVATO® is not to be delivered directly to patients.
SPRAVATO® is a nasal spray that is administered under the supervision of a healthcare professional. Certified SPRAVATO® treatment centers need to provide the infrastructure and operational support to prepare and monitor patients during self-administration and prior to release from the treatment center.
If you are interested in establishing your practice as a treatment center for SPRAVATO®, you must enroll in the SPRAVATO® REMS and become certified.
To find a certified SPRAVATO® treatment center, you or your patients may visit www.spravatohcp.com/findacenter.
If a patient misses treatment sessions, provided there is no worsening of their depressive symptoms, the patient should continue the current dosing schedule.
For patients who miss treatment sessions during maintenance treatment and have worsening of depression symptoms, per clinical judgment, consider returning to the previous dosing schedule (e.g., if doses missed during weekly dosing, revert to twice weekly dosing).
No, under the REMS, SPRAVATO® must be administered in a certified healthcare setting. Due to the possibility of delayed or prolonged sedation or dissociation in some cases, patients should be monitored by a healthcare provider for at least 2 hours following each treatment session, or until the clinician determines the patient is safe to leave.
SPRAVATO® is also administered under REMS due to the potential for abuse and misuse. Consider the risks and benefits of prescribing SPRAVATO® prior to using in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse.
The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®.
Caution patients that SPRAVATO® may impair their ability to drive or operate machinery. Instruct patients not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.
1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.